CD19 Antibody

NSJ Bioreagents
Product Code: NSJ-V8656SAF
Product Group: Primary Antibodies
Supplier: NSJ Bioreagents
CodeSizePrice
NSJ-V8656SAF-100UG100 ug£534.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Host Type: Mouse
Antibody Isotype: Mouse IgG2a kappa
Antibody Clonality: Recombinant Antibody
Antibody Clone: rCD19/4591
Regulatory Status: RUO
Target Species: Human
Application: Immunohistochemistry- Paraffin Embedded (IHC-P)
Storage:
Store the recombinant CD19 antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).

Images

1 / 3
IHC staining of FFPE human lymph node with recombinant CD19 antibody. HIER: boil tissue sections in pH 9 10mM Tris with 1mM EDTA for 20 min and allow to cool before testing.
2 / 3
IHC staining of FFPE human lymph node with recombinant CD19 antibody. HIER: boil tissue sections in pH 9 10mM Tris with 1mM EDTA for 20 min and allow to cool before testing.
3 / 3
SDS-PAGE analysis of purified, BSA-free recombinant CD19 antibody as confirmation of integrity and purity.

IHC staining of FFPE human lymph node with recombinant CD19 antibody. HIER: boil tissue sections in pH 9 10mM Tris with 1mM EDTA for 20 min and allow to cool before testing.
IHC staining of FFPE human lymph node with recombinant CD19 antibody. HIER: boil tissue sections in pH 9 10mM Tris with 1mM EDTA for 20 min and allow to cool before testing.
SDS-PAGE analysis of purified, BSA-free recombinant CD19 antibody as confirmation of integrity and purity.

Documents

Further Information

Application Details:
Immunohistochemistry (FFPE): 1-2ug/ml for 30 minutes at RT
Application Note:
Optimal dilution of the recombinant CD19 antibody should be determined by the researcher.
Description:
CD19 is a transmembrane glycoprotein that contains two extracellular immunoglobulin-like domains. CD19 is present in both benign and malignant B-cells and is considered to be the most reliable surface marker of this lineage over a wide range of maturational stages. In normal lymphoid tissue, CD19 is observed in germinal centers, in mantle zone cells, and in scattered cells of the inter-follicular areas. Anti-CD19 exhibits an overall immunoreactivity pattern similar to those of the antibodies against CD20 and CD22. However, in contrast to CD20, expression of CD19 is continuous throughout B-cell development and through terminal differentiation of B-cells into plasma cells. Anti-CD19 positivity is seen in the vast majority of B-cell neoplasms commonly at a lower intensity than normal B-cell counterparts. Plasma cell neoplasms are nearly always negative, as are T-cell neoplasms.
Format:
Purified
Formulation:
1 mg/ml in 1X PBS; BSA free, sodium azide free
Immunogen:
A portion of amino acids 456-556 from the human protein was used as the immunogen for the recombinant CD19 antibody.
Limitation:
This recombinant CD19 antibody is available for research use only.
Localization:
Cell surface, cytoplasmic
Purity:
Protein G affinity chromatography
Uniprot #:
P15391